Skip to main content
Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

HOME
ABOUT
AREAS OF FOCUS
- Close
- PIPELINE
- POSTERS & PUBLICATIONS
INVESTOR RELATIONS
PRESS
- Close
- PRESS RELEASES
CONTACT US

Main Content

ADVANCING ANTIBODY DRUG

CONJUGATES WITH NOVEL

IMMUNO-ONCOLOGY PAYLOADS

CORPORATE PRESENTATION CORPORATE PRESENTATION

RECENT PRESS RELEASES

Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

May 12, 2026

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

April 27, 2026

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

April 21, 2026

Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

April 20, 2026

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC

April 9, 2026

Footer

FOLLOW US

Privacy Statement

Copyright © 2026 · Akari Therapeutics · Site Designed by Polus Digital, Inc.